JP2014500724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500724A5 JP2014500724A5 JP2013538972A JP2013538972A JP2014500724A5 JP 2014500724 A5 JP2014500724 A5 JP 2014500724A5 JP 2013538972 A JP2013538972 A JP 2013538972A JP 2013538972 A JP2013538972 A JP 2013538972A JP 2014500724 A5 JP2014500724 A5 JP 2014500724A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- protein
- homologous
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 159
- 102000004169 proteins and genes Human genes 0.000 claims description 138
- 108090000623 proteins and genes Proteins 0.000 claims description 138
- 239000012634 fragment Substances 0.000 claims description 68
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 60
- 230000002163 immunogen Effects 0.000 claims description 57
- 125000000539 amino acid group Chemical group 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 26
- 108091026890 Coding region Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 21
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 16
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 16
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 10
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 10
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 6
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 6
- 102000046689 human FOLH1 Human genes 0.000 description 5
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 2
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317610P | 2010-11-12 | 2010-11-12 | |
| US61/413,176 | 2010-11-12 | ||
| US41781710P | 2010-11-29 | 2010-11-29 | |
| US61/417,817 | 2010-11-29 | ||
| PCT/US2011/060592 WO2012065164A2 (en) | 2010-11-12 | 2011-11-14 | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016026602A Division JP6310952B2 (ja) | 2010-11-12 | 2016-02-16 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500724A JP2014500724A (ja) | 2014-01-16 |
| JP2014500724A5 true JP2014500724A5 (enExample) | 2014-12-18 |
| JP6077450B2 JP6077450B2 (ja) | 2017-02-08 |
Family
ID=46051609
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538972A Active JP6077450B2 (ja) | 2010-11-12 | 2011-11-14 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2016026602A Active JP6310952B2 (ja) | 2010-11-12 | 2016-02-16 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2017222784A Active JP7142427B2 (ja) | 2010-11-12 | 2017-11-20 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020046459A Active JP7572152B2 (ja) | 2010-11-12 | 2020-03-17 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020211554A Withdrawn JP2021045171A (ja) | 2010-11-12 | 2020-12-21 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2023160203A Pending JP2023171837A (ja) | 2010-11-12 | 2023-09-25 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016026602A Active JP6310952B2 (ja) | 2010-11-12 | 2016-02-16 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2017222784A Active JP7142427B2 (ja) | 2010-11-12 | 2017-11-20 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020046459A Active JP7572152B2 (ja) | 2010-11-12 | 2020-03-17 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020211554A Withdrawn JP2021045171A (ja) | 2010-11-12 | 2020-12-21 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2023160203A Pending JP2023171837A (ja) | 2010-11-12 | 2023-09-25 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8927692B2 (enExample) |
| EP (3) | EP3536703B1 (enExample) |
| JP (6) | JP6077450B2 (enExample) |
| KR (5) | KR102364214B1 (enExample) |
| CN (2) | CN106434676B (enExample) |
| AU (1) | AU2011325893B2 (enExample) |
| BR (1) | BR112013011705B1 (enExample) |
| CA (1) | CA2817709C (enExample) |
| DK (1) | DK2638055T3 (enExample) |
| EA (1) | EA027315B1 (enExample) |
| ES (1) | ES2718846T3 (enExample) |
| MX (3) | MX358725B (enExample) |
| PL (1) | PL3536703T3 (enExample) |
| SI (1) | SI3536703T1 (enExample) |
| WO (1) | WO2012065164A2 (enExample) |
| ZA (1) | ZA201303390B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| KR102364214B1 (ko) * | 2010-11-12 | 2022-02-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
| PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| CN105457021A (zh) * | 2012-05-04 | 2016-04-06 | 辉瑞公司 | 前列腺相关抗原及基于疫苗的免疫治疗疗法 |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| MX364732B (es) * | 2012-12-13 | 2019-05-06 | Univ Pennsylvania | Vacuna contra el tumor de wilms 1. |
| KR20150093834A (ko) | 2012-12-13 | 2015-08-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ｄｎａ 항체 작제물 및 그 이용 방법 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2014144885A2 (en) * | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| KR102006527B1 (ko) * | 2013-11-01 | 2019-08-02 | 화이자 인코포레이티드 | 전립선-연관 항원의 발현을 위한 벡터 |
| CA3177878A1 (en) | 2014-04-23 | 2015-10-29 | Modernatx, Inc. | Nucleic acid vaccines |
| AU2015355126B9 (en) | 2014-12-01 | 2020-03-26 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| KR20230012070A (ko) * | 2016-03-21 | 2023-01-25 | 데이비드 비. 웨이너 | Dna 항체 작제물 및 이의 사용 방법 |
| US20190125852A1 (en) * | 2016-06-03 | 2019-05-02 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| CN106119231A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种肿瘤抗原psa的ctl识别表位肽及其应用 |
| CN106581668B (zh) * | 2016-12-31 | 2020-03-24 | 广州姿生生物科技有限公司 | 一种抗原表位肽组合物及其应用 |
| PT3737397T (pt) * | 2017-12-13 | 2023-02-28 | Inovio Pharmaceuticals Inc | Vacinas anticancro direcionadas contra prame e utilizações das mesmas |
| CN111308327B (zh) * | 2019-12-02 | 2021-01-26 | 电子科技大学 | 模拟电路故障定位与故障元件参数辨识方法 |
| CN117120617A (zh) * | 2021-02-05 | 2023-11-24 | St制药株式会社 | 新型核酸分子 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| DE4090351T1 (de) | 1989-03-08 | 1997-07-24 | Health Research Inc | Rekombinantes Pockenvirus-Wirtsselektionssystem |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| ES2090129T3 (es) | 1989-03-31 | 1996-10-16 | Univ Washington | Vacunas que contienen microorganismos tipo phop avirulentos. |
| ES2070997T3 (es) | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
| US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| EP0668777B2 (en) * | 1992-11-05 | 2011-02-09 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| WO1994016737A1 (en) | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP0708659A4 (en) | 1993-06-07 | 2000-08-23 | Genentech Inc | HIV ENVELOPE POLYPEPTIDES |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US6630305B1 (en) * | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| ES2273408T3 (es) | 1997-04-03 | 2007-05-01 | Electrofect As. | Metodo para introducir medicamentos y acidos nucleicos en el musculo esqueletico. |
| KR20010020571A (ko) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션 |
| ATE437947T1 (de) * | 1998-06-01 | 2009-08-15 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| US6833438B1 (en) * | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| EP1100579B1 (en) | 1998-07-13 | 2015-09-02 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6136703A (en) | 1998-09-03 | 2000-10-24 | Micron Technology, Inc. | Methods for forming phosphorus- and/or boron-containing silica layers on substrates |
| JP2002526419A (ja) * | 1998-10-05 | 2002-08-20 | ファーメクサ エイ／エス | 治療上のワクチン注射のための新規な方法 |
| US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| AU7994200A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US20020081680A1 (en) * | 2000-04-17 | 2002-06-27 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| JP2005505271A (ja) | 2001-09-06 | 2005-02-24 | アジェンシス， インコーポレイテッド | 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質 |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| CA2495389A1 (en) | 2002-08-19 | 2004-02-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA2504593C (en) | 2002-11-04 | 2016-08-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| EP1629088B1 (en) | 2003-05-30 | 2012-01-11 | Agensys, Inc. | Prostate stem cell antigen (psca) variants and subsequences thereof |
| US7238522B2 (en) | 2003-05-30 | 2007-07-03 | Advisys, Inc. | Devices and methods for biomaterial production |
| WO2005071093A2 (en) | 2004-01-23 | 2005-08-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Chimpanzee adenovirus vaccine carriers |
| WO2005117964A2 (en) * | 2004-05-27 | 2005-12-15 | Centocor, Inc. | Cynomolgus prostate specific antigen |
| KR100647847B1 (ko) * | 2005-05-27 | 2006-11-23 | 크레아젠 주식회사 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 |
| WO2007002149A2 (en) * | 2005-06-21 | 2007-01-04 | Cyto Pulse Sciences, Inc. | Methods and compositions relating to a vaccine against prostate cancer |
| KR101357685B1 (ko) * | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| EP2845866B1 (en) | 2006-10-27 | 2017-05-03 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| JP5744719B2 (ja) * | 2008-04-04 | 2015-07-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
| EP2727606A3 (en) * | 2008-09-08 | 2015-09-23 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| JP5753090B2 (ja) * | 2008-10-29 | 2015-07-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改良型ｈｃｖワクチンおよびその使用方法 |
| CA3001374A1 (en) * | 2008-11-17 | 2010-05-20 | Vgx Pharmaceuticals, Llc | Antigens that elicit immune response against flavivirus and methods of using same |
| KR102364214B1 (ko) * | 2010-11-12 | 2022-02-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| CN104168912B (zh) * | 2011-11-10 | 2016-08-24 | 北京艾棣维欣生物技术有限公司 | 促进剂-dna组合疫苗 |
| WO2018064588A2 (en) * | 2016-09-30 | 2018-04-05 | Weiner, David | Tert immunogenic compositions and methods of treatment using the same |
-
2011
- 2011-11-14 KR KR1020207019047A patent/KR102364214B1/ko active Active
- 2011-11-14 KR KR1020177035855A patent/KR102011026B1/ko active Active
- 2011-11-14 CN CN201610649676.2A patent/CN106434676B/zh active Active
- 2011-11-14 SI SI201131990T patent/SI3536703T1/sl unknown
- 2011-11-14 DK DK11839215.8T patent/DK2638055T3/en active
- 2011-11-14 WO PCT/US2011/060592 patent/WO2012065164A2/en not_active Ceased
- 2011-11-14 AU AU2011325893A patent/AU2011325893B2/en active Active
- 2011-11-14 EP EP19150850.6A patent/EP3536703B1/en active Active
- 2011-11-14 ES ES11839215T patent/ES2718846T3/es active Active
- 2011-11-14 MX MX2016013461A patent/MX358725B/es unknown
- 2011-11-14 EP EP21175561.6A patent/EP3909973A3/en not_active Withdrawn
- 2011-11-14 KR KR1020137014954A patent/KR101939150B1/ko active Active
- 2011-11-14 PL PL19150850T patent/PL3536703T3/pl unknown
- 2011-11-14 MX MX2018010616A patent/MX421208B/es unknown
- 2011-11-14 KR KR1020197023373A patent/KR102131276B1/ko active Active
- 2011-11-14 MX MX2013005195A patent/MX346784B/es active IP Right Grant
- 2011-11-14 JP JP2013538972A patent/JP6077450B2/ja active Active
- 2011-11-14 BR BR112013011705-2A patent/BR112013011705B1/pt active IP Right Grant
- 2011-11-14 CN CN201180064660.0A patent/CN103314002B/zh active Active
- 2011-11-14 US US13/883,978 patent/US8927692B2/en active Active
- 2011-11-14 KR KR1020227004853A patent/KR102557275B1/ko active Active
- 2011-11-14 EA EA201390689A patent/EA027315B1/ru not_active IP Right Cessation
- 2011-11-14 CA CA2817709A patent/CA2817709C/en active Active
- 2011-11-14 EP EP11839215.8A patent/EP2638055B1/en active Active
-
2013
- 2013-05-09 ZA ZA2013/03390A patent/ZA201303390B/en unknown
-
2014
- 2014-11-24 US US14/552,030 patent/US9399056B2/en active Active
-
2016
- 2016-02-16 JP JP2016026602A patent/JP6310952B2/ja active Active
- 2016-07-11 US US15/207,271 patent/US9913885B2/en active Active
-
2017
- 2017-11-20 JP JP2017222784A patent/JP7142427B2/ja active Active
-
2018
- 2018-01-31 US US15/884,594 patent/US11045535B2/en active Active
-
2020
- 2020-03-17 JP JP2020046459A patent/JP7572152B2/ja active Active
- 2020-12-21 JP JP2020211554A patent/JP2021045171A/ja not_active Withdrawn
-
2021
- 2021-06-28 US US17/360,342 patent/US11980659B2/en active Active
-
2023
- 2023-09-25 JP JP2023160203A patent/JP2023171837A/ja active Pending
-
2024
- 2024-05-10 US US18/660,509 patent/US20250101399A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500724A5 (enExample) | ||
| Dalvie et al. | Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice | |
| ES2839880T3 (es) | Vacuna contra el VRS | |
| AU2015220369B2 (en) | UspA2 protein constructs and uses thereof | |
| JP2009544333A5 (enExample) | ||
| JP2013526837A5 (enExample) | ||
| CN107427571A (zh) | 基于纳米颗粒的新型多价疫苗 | |
| CN114127101A (zh) | 用于治疗或预防呼吸道感染的亚单位疫苗 | |
| JP2014507146A5 (enExample) | ||
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| EP1578922A2 (en) | Replikin peptides in rapid replication of glioma cells and in influenza epidemics | |
| BR112015029635B1 (pt) | Polipeptídeo do domínio de haste da hemaglutinina da gripe e composição | |
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| JP2013518599A5 (enExample) | ||
| EP4190906A1 (en) | Engineered polypeptides derived from adenoviral fibre protein and vlps containing the polypeptides | |
| JP2017521425A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| CN107847575A (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| JP2012516140A5 (enExample) | ||
| EP4110385A1 (en) | Compositions comprising ltb and pathogenic antigens, and use thereof | |
| CN109575142B (zh) | 一种cd4辅助性t细胞表位融合肽及其疫苗 | |
| WO2015002134A1 (ja) | 細胞性免疫誘導ワクチン | |
| CN117279659A (zh) | 人偏肺病毒疫苗 | |
| ES2780525T3 (es) | Proteínas quiméricas basadas en cyaa que comprenden un polipéptido heterólogo y sus usos en la inducción de respuestas inmunes | |
| JP2020502075A5 (enExample) | ||
| Cho et al. | Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus |